

CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition according to claim 1, comprising (*R*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine substantially free of the corresponding (*S*)-enantiomer, or a pharmaceutically acceptable salt thereof.
3. The composition according to claim 2 wherein the amount of (*R*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 85% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.
4. The composition according to claim 3 wherein the amount of (*R*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 90% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.
5. The composition according to claim 4 wherein the amount of (*R*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 95% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

6. The composition according to claim 5 wherein the amount of (*R*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 99% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

7. The pharmaceutical composition according to claim 1, comprising (*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine substantially free of the corresponding (*R*)-enantiomer, or a pharmaceutically acceptable salt thereof.

8. The composition according to claim 7 wherein the amount of (*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 85% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

9. The composition according to claim 8 wherein the amount of (*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 90% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

10. The composition according to claim 9 wherein the amount of (*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or pharmaceutically acceptable salt thereof, in the composition is 95% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

11. The composition according to claim 10 wherein the amount of (*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine,

-45-

epine, or pharmaceutically acceptable salt thereof, in the composition is 99% by weight or more of the total weight of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine.

12. The pharmaceutical composition according to claim 1, comprising a racemic mixture of (*R*)- and (*S*)-enantiomers of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine, or a pharmaceutically acceptable salt thereof.

13. A method of treating an LTB₄-mediated inflammatory disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 1.

14. A method of treating an LTB₄-mediated inflammatory disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 2.

15. A method of treating an LTB₄-mediated inflammatory disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 7.

16. A method of treating an LTB₄-mediated inflammatory disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 12.

17. The method of claim 13 wherein the disorder is inflammatory bowel disease.

-46-

18. The method of claim 13 wherein the disorder is ulcerative colitis.
19. The method of claim 13 wherein the disorder is psoriasis.
20. The method of claim 13 wherein the disorder is rheumatoid arthritis.
21. The method of claim 13 wherein the disorder is Crohn's Disease.
22. The method of claim 13 wherein the disorder is radiation-induced gastrointestinal inflammation.
23. A method of preventing or delaying the onset of an inflammatory disorder mediated by LTB_4 in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 1.
24. A method of preventing or delaying the onset of an inflammatory disorder mediated by LTB_4 in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 2.
25. A method of preventing or delaying the onset of an inflammatory disorder mediated by LTB_4 in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 7.
26. A method of preventing or delaying the onset of an inflammatory disorder mediated by LTB_4 in an individual who is at risk of developing an

-47-

inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 12.

27. A method of treating an TXA_2 -mediated disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 1.

28. A method of treating an TXA_2 -mediated disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 2.

29. A method of treating an TXA_2 -mediated disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 7.

30. A method of treating an TXA_2 -mediated disorder in an individual in need of such treatment, comprising administering to said individual a therapeutically effective amount of the composition according to claim 12.

31. The method according to claim 27 wherein the TXA_2 -mediated disorder comprises a chronic inflammatory disorder.

32. The method according to claim 31, wherein the chronic inflammatory disorder is selected from the group consisting of chronic fatigue syndrome/fibromyalgia, infertility, osteonecrosis of the jaw, multiple sclerosis, depression, autism, Crohn's Disease, Inflammatory Bowel Disease, late Lyme Disease, Sjogren's Syndrome, transient ischemic attack, attention deficit disorder and Parkinson's Disease.

-48-

33. The method of claim 27 wherein the disorder mediated by thromboxane A₂ involves an immune system activation of coagulation.

34. The method according to claim 27 wherein the disorder mediated by thromboxane A₂ is pain.

35. The method according to claim 27 wherein the disorder mediated by thromboxane A₂ is asthma.

36. The method according to claim 27 wherein the disorder mediated by thromboxane A₂ is angiogenesis associated with a developing tumor.

37. A method of preventing or delaying the onset of an inflammatory disorder mediated by TXA₂ in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 1.

38. A method of preventing or delaying the onset of an inflammatory disorder mediated by TXA₂ in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 2.

39. A method of preventing or delaying the onset of an inflammatory disorder mediated by TXA₂ in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 7.

-49-

40. A method of preventing or delaying the onset of an inflammatory disorder mediated by TXA_2 in an individual who is at risk of developing an inflammatory disease state, said method comprising administering to said individual a therapeutically effective amount of the composition according to claim 12.